Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518178 | 0.83 | KIF11 (0.49) | KDM4EUSP2HPGDHSD17B10NPC1 | |
| Hydrochloric Acid SCHEMBL30729484 | 0.82 | KIF11 (0.47) | KDM4EUSP2HPGDHSD17B10NPC1 | |
| SCHEMBL26134841 | 0.79 | KIF11 (0.52) | SCN2AKIF11 | |
| SCHEMBL14931973 | 0.79 | KDM4E (0.66) | KDM4EHPGDHSD17B10CYP1A2SMN1; SMN2 | |
| SCHEMBL28281813 | 0.78 | KDM4E (0.70) | KDM4EUSP2HPGDHSD17B10NPC1 | |
| SCHEMBL308253 | 0.77 | KDM4E (0.69) | KDM4EUSP2HPGDHSD17B10CYP1A2 | |
| Hydrochloric Acid SCHEMBL30729482 | 0.77 | KDM4E (0.64) | KDM4EUSP2HPGDHSD17B10NPC1 | |
| SCHEMBL6890851 | 0.77 | KDM4E (0.68) | KDM4EUSP2HPGDHSD17B10NPC1 | |
| SCHEMBL3154080 | 0.77 | KDM4E (1.00) | KDM4EUSP2HPGDHSD17B10NPC1 | |
| SCHEMBL27666763 | 0.77 | KDM4E (0.62) | KDM4EUSP2HPGDHSD17B10PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | KDM4E 154/4885USP2 574/4885HPGD 3239/4885 |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | KDM4E 154/4885USP2 574/4885HPGD 3239/4885 |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | KDM4E 154/4885USP2 574/4885HPGD 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.